The role of mitochondria in the resistance of melanoma to PD-1 inhibitors
Abstract Malignant melanoma is one of the most common tumours and has the highest mortality rate of all types of skin cancers worldwide. Traditional and novel therapeutic approaches, including surgery, targeted therapy and immunotherapy, have shown good efficacy in the treatment of melanoma. At pres...
Main Authors: | Fei Du, Lu-han Yang, Jiao Liu, Jian Wang, Lianpeng Fan, Suwit Duangmano, Hao Liu, Minghua Liu, Jun Wang, Xiaolin Zhong, Zhuo Zhang, Fang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-023-04200-9 |
Similar Items
-
CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma
by: Zhuo Zhang, et al.
Published: (2023-12-01) -
Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway
by: Zhuo Zhang, et al.
Published: (2023-04-01) -
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
by: M. Amini-Adle, et al.
Published: (2018-07-01) -
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01) -
Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population
by: Chen Wang, et al.
Published: (2023-04-01)